
GNWSF
Healthcare · Diagnostics & Research · $23.5M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Apr 1, 2021 | Time not confirmed | — | -0.12 | — |
| Nov 20, 2020 | Time not confirmed | — | -0.09 | — |
| Aug 14, 2020 | Time not confirmed | — | 0.00 | — |
| May 20, 2020 | Time not confirmed | — | -0.01 | — |
| Nov 14, 2019 | Time not confirmed | — | 0.01 | — |
| Aug 14, 2019 | Time not confirmed | — | -0.00 | — |
| Apr 3, 2019 | Time not confirmed | — | -0.05 | — |
| Dec 31, 2018 | Time not confirmed | — | -0.00 | — |
| Nov 13, 2018 | Time not confirmed | — | -0.00 | — |
| Jun 30, 2018 | Time not confirmed | — | -0.16 | — |
| Mar 31, 2018 | Time not confirmed | — | -0.04 | — |
StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's…